Konferenser och symposier HER2 - state of the art jubilee symposium
This symposium has been moved to 2021.
2020 it is 20 years since the approval of HER2 targeted therapies for the treatment of HER2 positive breast cancer in Sweden and Europe.
The objectives of this symposium include improving our understanding of HER2 biology and testing, increasing our knowledge of treating HER2-positive breast cancer, and learning more about the very latest developments surrounding future predictive markers of breast cancer.
The symposium is multidisciplinary, oriented towards physicians, researchers, pathologists and others involved in the understanding, analysis, diagnosis, and treatment of breast cancer.
You will hear a distinguished group of oncology experts give cutting-edge presentations on HER2-positive breast cancer and other relevant therapy-predictive factors. These are highly topical issues and the data presented will undoubtedly inspire much discussion and interaction between presenters and participants alike.
We invite you to join us in Stockholm – to contribute to this Jubilee HER2 State of the Art symposium and help advance the diagnosis and treatment of HER2-positive breast cancer.
If you have any questions or would like additional information about the symposium, please contact Akademikonferens,
Registration must be carried out by using the link:
https://reg.akademikonferens.se/her2020 no later than May 20.
If the number of registrations for the symposium exceeds the number of places available, places will be allocated with a view to achieving a balanced regional spread.
The symposium is free of charge but if you fail to appear without reporting it, you will be charged a cost of SEK 500.